Drugs / E-CEL UVEC Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06456073 | Sep 2024 → Dec 2026 expected | ulcer of anus and rectum | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07557134 | May 2027 → Sep 2029 expected | anal fistula | Angiocrine Bioscience | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-CEL UVEC Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557134 ↗ |
| Known as | AB-207 | “E-CEL UVEC cells (AB-207)” NCT06456073 ↗ |
| Modality | Cell therapy | “E-CEL UVEC cell therapy” NCT06456073 ↗ |
| Route | Other | “percutaneous injections” NCT06456073 ↗ |